Results 51 to 60 of about 737 (141)

DataSheet1_Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials.pdf [PDF]

, 2023
Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu, Ke-Wei Zhu (5078000)
core   +1 more source

Image_1_Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study.tif [PDF]

, 2023
BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking.
Guangtong Deng (7379081), Rui Wei (444580), Xiaomin Wang (102596), Yating Dian (10583633), Furong Zeng (7379075), Qian Zhou (125859)   +5 more
core   +1 more source

Azvudine therapy of common COVID‐19 in hemodialysis patients

Journal of Medical Virology, 2023
AbstractThere is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially on the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients.
Shunlai Shang, Bo Fu, Yanqiu Geng, Jian Zhang, Dawei Zhang, Fenglin Xiao, Zhaojun Sheng, Jingbo Zhai, Wenge Li, Xiangmei Chen, Chunfu Zheng, Qinggang Li   +11 more
openaire   +2 more sources

DataSheet1_Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.docx [PDF]

, 2023
Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety.Methods: We conducted a retrospective cohort study involving
Xue-Peng Gong (17140423), Lu Zeng (686537), An-Hua Wei (5985029), Wen-Ting Zhang (1789032), Lin Gui (1958380), Juan Li (146180), Lu Wang (45927), Dong Liu (115204)   +7 more
core   +1 more source

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study. [PDF]

Front Pharmacol
ObjectiveTo explore the effectiveness and safety of azvudine and nirmatrelvir-ritonavir in a real-world setting.MethodsThis retrospective cohort study included adult patients with confirmed COVID-19 who received azvudine or nirmatrelvir-ritonavir ...
Chen J, Liu Z, Liu R, Su C, Yang Y, Wang Z.   +5 more
europepmc   +3 more sources

The efficacy of azvudine in treating hospitalized COVID-19 patients: a retrospective single-center cohort analysis. [PDF]

J Thorac Dis
Although coronavirus disease 2019 (COVID-19) is no longer classified as a Public Health Emergency of International Concern (PHEIC), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to undergo genetic mutations, leading to persistent public health challenges.
Lei H, Ye YW, Zhou YJ, Mao YF, Fang Y, Chen PP, You WW, Li S, Xu YY.   +8 more
europepmc   +3 more sources

Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge. [PDF]

Front Immunol
BackgroundLittle is known about immunophenotyping characteristics and clinical outcomes of COVID-19 patients treated with azvudine during the Omicron variant surge.MethodsThis study enrolled patients diagnosed with COVID-19 from December 2022 to February
Qiu M, Song X, Zhang Q, Zou S, Pang L, Nian X.   +5 more
europepmc   +3 more sources

Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis [PDF]

, 2023
At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19.
Fangyuan Tian (1570417), Zhaoyan Chen (461261)   +1 more
core   +3 more sources

Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China [PDF]

, 2023
Background: The sixty-day effects of initial composite interventions for the treatment of severely and critically ill patients with COVID-19 are not fully assessed.
Chengnan Guo, Fengdi Zhang, Jianrong Hu, Liou Cao, Runsheng Guo, Gang Huang, Xuyuan Huang, Jiasheng Shao, Rong Fan   +8 more
core   +1 more source

Data_Sheet_3_Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients.pdf [PDF]

, 2023
BackgroundIn 2019, a highly pathogenic coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surfaced and resulted in the outbreak of coronavirus disease 2019 (COVID-19).
Pingsheng Lei (5240192), Aline dos Santos Moreira (17203549), Cléber Glória Silva (17203552), Paula Gebe Abreu Cabral (6515375), Renato Martins da Silva (14787250), Antônio Brazil Viana Junior (14787268), Raul Ferraz Arruda (14787253), Sávio Bastos de Souza (6700298), Arícia Leone Evangelista Monteiro de Assis (14787259), Wim Maurits Sylvain Degrave (16933380), Junbiao Chang (1523644), Sheila Passos de Figueiredo Cabral (14787256)   +11 more
core   +1 more source